156 related articles for article (PubMed ID: 20164785)
1. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.
Chan KY; Edvinsson L; Eftekhari S; Kimblad PO; Kane SA; Lynch J; Hargreaves RJ; de Vries R; Garrelds IM; van den Bogaerdt AJ; Danser AH; Maassenvandenbrink A
J Pharmacol Exp Ther; 2010 Sep; 334(3):746-52. PubMed ID: 20573757
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
[TBL] [Abstract][Full Text] [Related]
4. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
Ho TW; Olesen J; Dodick DW; Kost J; Lines C; Ferrari MD
Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
[TBL] [Abstract][Full Text] [Related]
5. Molecule of the month. Telcagepant.
Drug News Perspect; 2009 Mar; 22(2):115. PubMed ID: 19330169
[No Abstract] [Full Text] [Related]
6. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
Dodick DW; Kost J; Assaid C; Lines C; Ho TW
Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
[TBL] [Abstract][Full Text] [Related]
7. CGRP-receptor antagonism in migraine treatment.
Edvinsson L
Lancet; 2008 Dec; 372(9656):2089-90. PubMed ID: 19036426
[No Abstract] [Full Text] [Related]
8. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
[TBL] [Abstract][Full Text] [Related]
9. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
Tfelt-Hansen P
Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
[TBL] [Abstract][Full Text] [Related]
10. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
Tepper SJ; Cleves C
Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca
Erdling A; Sheykhzade M; Edvinsson L
J Headache Pain; 2017 Dec; 18(1):61. PubMed ID: 28560541
[TBL] [Abstract][Full Text] [Related]
12. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist.
Hasbak P; Saetrum Opgaard O; Eskesen K; Schifter S; Arendrup H; Longmore J; Edvinsson L
J Pharmacol Exp Ther; 2003 Jan; 304(1):326-33. PubMed ID: 12490608
[TBL] [Abstract][Full Text] [Related]
13. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.
Edvinsson L; Chan KY; Eftekhari S; Nilsson E; de Vries R; Säveland H; Dirven CM; Danser AH; MaassenVanDenBrink A
Cephalalgia; 2010 Oct; 30(10):1233-40. PubMed ID: 20855369
[TBL] [Abstract][Full Text] [Related]
14. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors.
Waugh DJ; Bockman CS; Smith DD; Abel PW
J Pharmacol Exp Ther; 1999 Jun; 289(3):1419-26. PubMed ID: 10336535
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
Cui XP; Ye JX; Lin H; Mu JS; Lin M
Pain Pract; 2015 Feb; 15(2):124-31. PubMed ID: 24382126
[TBL] [Abstract][Full Text] [Related]
16. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
[TBL] [Abstract][Full Text] [Related]
17. Ethanol dilates coronary arteries and increases coronary flow via transient receptor potential vanilloid 1 and calcitonin gene-related peptide.
Gazzieri D; Trevisani M; Tarantini F; Bechi P; Masotti G; Gensini GF; Castellani S; Marchionni N; Geppetti P; Harrison S
Cardiovasc Res; 2006 Jun; 70(3):589-99. PubMed ID: 16579978
[TBL] [Abstract][Full Text] [Related]
18. Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries.
Edvinsson L; Ahnstedt H; Larsen R; Sheykhzade M
Acta Physiol (Oxf); 2014 Apr; 210(4):811-22. PubMed ID: 24330354
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
Ho TW; Ho AP; Chaitman BR; Johnson C; Mathew NT; Kost J; Fan X; Aurora SK; Brandes JL; Fei K; Beebe L; Lines C; Krucoff MW
Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
